Clinical impact of tumor-infiltrating CD45RO+ memory T cells on human gastric cancer

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1756-1762

  Wakatsuki, Kohei ^a   Sho, Masayuki ^a   Yamato, Ichiro ^a   Takayama, Tomoyoshi ^a   Matsumoto, Sohei ^a   Tanaka, Tetsuya ^a   Migita, Kazuhiro ^a   Ito, Masahiro ^a   Hotta, Kiyohiko ^a   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

CD45RO; Gastric cancer; Memory T cell; Prognosis; Surgery

Indexed keywords

CD45RO ANTIGEN; GAMMA INTERFERON;

ADAPTIVE IMMUNITY; ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER TISSUE; CELL FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; LEUKOCYTE FUNCTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; PERITONEUM CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; CD4-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84876212828     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2302     Document Type: Article

References (46)

1. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E and Buyse M: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303: 1729-1737, 2010.
2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A and Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007. (Pubitemid 350044801)
3. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Ji J, Yeh TS, Button P, Sirzen F and Noh SH; CLASSIC trial investigators: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379: 315-321, 2012.
4. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29: 4387-4393, 2011.
5. Gooden MJ, de Bock GH, Leffers N, Daemen T and Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105: 93-103, 2011.
6. Hwang WT, Adams SF, Tahirovic E, Hagemann IS and Coukos G: Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 124: 192-198, 2012.
7. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma VM: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324, 1997. (Pubitemid 27285785)
8. Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M and Rosenberg SA: Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 65: 413-421, 1996. (Pubitemid 26083244)
9. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS and Ogino S: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222: 350-366, 2010.
10. Hiraoka N: Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol 15: 544-551, 2010.
11. + B cells: the other tumor-infiltrating lympho cytes. J Immunol 185: 4977-4982, 2010.
12. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003. (Pubitemid 36077915)
13. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494, 1998.
14. Wada Y, Nakashima O, Kutami R, Yamamoto O and Kojiro M: Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27: 407-414, 1998. (Pubitemid 28081054)
15. Dunn GP, Old LJ and Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360, 2004. (Pubitemid 38680426)
16. Johansson M, Denardo DG and Coussens LM: Polarized immune responses differentially regulate cancer development. Immunol Rev 222: 145-154, 2008. (Pubitemid 351430362)
17. + IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105: 15505-15510, 2008.
18. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R and Zou W: Phenotype, distribution, genera tion, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149, 2009.
19. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP and Zheng L: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980-989, 2009.
20. Wilke CM, Wu K, Zhao E, Wang G and Zou W: Prognostic significance of regulatory T cells in tumor. Int J Cancer 127: 748-758, 2010.
21. Curiel TJ: Regulatory T cells and treatment of cancer. Curr Opin Immunol 20: 241-246, 2008.
22. + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434, 2006.
23. + regulatory T cells affect the development and progression of hepatocarcino genesis. Clin Cancer Res 13: 902-911, 2007.
24. Charbonneau H, Tonks NK, Walsh KA and Fischer EH: The leukocyte common antigen (CD45): a putative receptor-linked protein tyrosine phosphatase. Proc Natl Acad Sci USA 85: 7182-7186, 1988.
25. Merkenschlager M and Beverley PC: Evidence for differential expression of CD45 isoforms by precursors for memory-depen dent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45RO (UCHL1). Int Immunol 1: 450-459, 1989. (Pubitemid 19263705)
26. Merkenschlager M, Terry L, Edwards R and Beverley PC: Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: implications for differential CD45 expression in T cell memory formation. Eur J Immunol 18: 1653-1661, 1988. (Pubitemid 19011570)
27. Zola H, Flego L, Macardle PJ, Donohoe PJ, Ranford J and Roberton D: The CD45RO (p180, UCHL1) marker: complexity of expression in peripheral blood. Cell Immunol 145: 175-186, 1992.
28. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR and Maino VC: Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 86: 1408-1419, 1995.
29. Michie CA, McLean A, Alcock C and Beverley PC: Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360: 264-265, 1992.
30. Gray D: Immunological memory. Annu Rev Immunol 11: 49-77, 1993.
31. Dutton RW, Bradley LM and Swain SL: T cell memory. Annu Rev Immunol 16: 201-223, 1998. (Pubitemid 28183364)
32. Sallusto F, Geginat J and Lanzavecchia A: Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763, 2004. (Pubitemid 38680440)
33. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006. (Pubitemid 44498003)
34. Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL and Kim WH: Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 99: 1704-1711, 2008.
35. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666, 2005. (Pubitemid 41817714)
36. + tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. BMC Cancer 10: 608, 2010.
37. Enomoto K, Sho M, Wakatsuki K, Takayama T, Matsumoto S, Nakamura S, Akahori T, Tanaka T, Migita K, Ito M and Nakajima Y: Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. Clin Exp Immunol 168: 186-191, 2012.
38. Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Konishi N, Hirao Y, Nonomura K and Nakajima Y: Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer 105: 1191-1196, 2011.
39. Sallusto F, Lenig D, Forster R, Lipp M and Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712, 1999.
40. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E and Lipp M: CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99: 23-33, 1999. (Pubitemid 29468627)
41. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101: 4260-4266, 2003.
42. Rosenberg SA, Dudley ME and Restifo NP: Cancer immuno therapy. N Engl J Med 359: 1072, 2008.
43. Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H and Nakajima Y: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 101: 1709-1716, 2009.
44. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M and Nakajima Y: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-2157, 2007. (Pubitemid 46649885)
45. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M and Nakajima Y: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11: 2947-2953, 2005. (Pubitemid 40525197)
46. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A and Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.